Summary: New Hampshire; Note Nov 11

  • ID: 2024227
  • November 2011
  • Region: New Hampshire
  • Standard & Poors
1 of 3

Standard & Poor's Ratings Services has affirmed its 'A-1+' rating on New Hampshire's commercial paper (CP) program GO bond anticipation notes (BANs), series A, based on the full faith and credit of the state. Under the CP program, New Hampshire issues GO BANs in the form of CP to finance various capital outlay projects for which state bonds have been authorized. The maximum principal amount of CP to be outstanding is $50 million. Additional liquidity support is provided by a credit agreement with U.S. Bank in the form of a line of credit that is scheduled to terminate Dec. 23, 2013. The agreement provides full backup for the principal amount of CP authorized, the maturity of which cannot be beyond...

Companies mentioned in this report are: New Hampshire
Action: Affirmed

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

This product consists of a Summary Analysis: Bi-annual (at least). An abbreviated analysis containing Standard & Poor's issuer credit ratings as of the time the article was published. The analysis includes a rating rationale - the basis on which the rating was assigned - and an outlook section if the issuer is not on CreditWatch. Financial statistics are not included.

Note: Product cover images may vary from those shown
2 of 3

New Hampshire

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.